The increase in holding from 44 per cent in the platform vaccine development company led by Prof Ian Frazer follows the recent milestone announcement that the genital herpes (HSV-2) vaccine being developed by Coridon is entering its first human trials.
The Phase 1 trial of the novel HSV-2 vaccine is aimed at both preventing the spread of the virus and offering a treatment to those infected.
Prof Frazer is also developing a next-generation therapeutic vaccine for human papilomarvirus (HPV) and associated cancers and this is also showing significant and positive progress, said Allied Healthcare Group CEO Lee Rodne.
"Both herpes and HPV are highly prevalent viral infections for which there is no therapeutic vaccine or cure available and as such represents a high global demand and clinical need for new novel vaccines and improved treatments," Rodne said.
"We continue to see exceptionally strong results and the delivery of key milestones from Professor Frazer's work in this space, and so we are driven to further invest and commercialise this high-potential technology."
Allied Healthcare Group and Prof Ian Frazer are developing the next-generation therapeutic vaccines, which are designed to not only prevent the spread of disease but to also treat those already infected.
There is no limit on who can benefit from a therapeutic vaccine and it could be applied to a broad range of viral diseases and cancers.
Genital herpes affects more than 1 in 6 Americans between the ages of 14 and 49 according to the Centers for Disease Control in the USA.
WHO estimates the number of people aged 15-49 years who were living with HSV-2 worldwide exceeds half a billion.
Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX "Small and Mid-cap" stocks with distribution in Australia, UK, North America and Hong Kong / China.